Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,055 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sodium Chloride (NaCl) 0.9 % Clear all
Terminated Phase 3 Interventional Results available

Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

NCT02687451
View directory record Official record
Conditions
Post-Operative Pain, Acute Pain
Interventions
Oxymorphone HCl, Placebo
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
0 Years to 2 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118
View directory record Official record
Conditions
Respiratory Tract Infection, Respiratory Syncytial Virus
Interventions
Clesrovimab, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Weeks to 8 Months
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
17
States / cities
Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose

NCT03999996
View directory record Official record
Conditions
Dengue Fever
Interventions
Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
13 Years to 63 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
8
States / cities
Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

NCT04368988
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 84 Years
Enrollment
1,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Sep 30, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

NCT06347003
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
52
States / cities
Garden Grove, California • Lake Forest, California • Montclair, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 30, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

NCT06226805
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
BB-031, Placebo
Drug
Lead sponsor
Basking Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Scottsdale, Arizona • Burlingame, California • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 30, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

Tocilizumab for the Treatment of Behcet's Syndrome

NCT01693653
View directory record Official record
Conditions
Behcet Syndrome
Interventions
Tocilizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Early Phase 1 Interventional

IV Tranexamic Acid Prior to Hysterectomy

NCT02911831
View directory record Official record
Conditions
Hysterectomy, Blood Loss, Surgical
Interventions
Tranexamic Acid, Sodium Chloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369727
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 30, 2026, 5:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients With Low Back Pain

NCT03709901
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Active Allograft, Placebo
Other
Lead sponsor
VIVEX Biologics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
13
States / cities
Santa Monica, California • Walnut Creek, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 30, 2026, 5:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
IVT GBS-06, Placebo
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 30, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional

Study Evaluating GAP-486 in Heart Rhythm

NCT00137293
View directory record Official record
Conditions
Arrhythmia
Interventions
GAP-486 (ZP-123), 0.9% Sodium Chloride, USP
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

NCT04019444
View directory record Official record
Conditions
Rabies, Rabies Immunisation
Interventions
ChAd155-RG, Placebo, Rabies Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT06375512
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ Vaccine (IN001), Placebo, Shingrix
Biological
Lead sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Industry
Eligibility
50 Years to 69 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 30, 2026, 5:59 AM EDT
Terminated Not applicable Interventional

Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis

NCT01996111
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
Procedure
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Sep 30, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT05286814
View directory record Official record
Conditions
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)

NCT06842121
View directory record Official record
Conditions
Parenteral Nutrition
Interventions
Sodium Glycerophosphate Injection, Sodium Phosphates Injection
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

NCT04801043
View directory record Official record
Conditions
Bacterial Infections
Interventions
XNW4107, Imipenem/Cilastatin, placebo
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 30, 2026, 5:59 AM EDT
Terminated Phase 3 Interventional Results available

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

NCT04571645
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dociparstat, Control
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Orange, California • Westwood, Kansas • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

PriMatrix for the Management of Diabetic Foot Ulcers

NCT03010319
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
PriMatrix Dermal Repair Scaffold, Secondary Dressings, Offloading device
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Carlsbad, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

Haloperidol for the Treatment of Nausea and Vomiting in the ED

NCT04764344
View directory record Official record
Conditions
Vomiting, Nausea, Abdominal Pain, Cannabis Use
Interventions
Haloperidol, Ondansetron
Drug
Lead sponsor
Western Michigan University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871
View directory record Official record
Conditions
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Sep 30, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids

NCT01967433
View directory record Official record
Conditions
Colonoscopy, Adjunct Anesthesia Medication
Interventions
Diphenhydramine, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 30, 2026, 5:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cells for Erectile Dysfunction Post RALP

NCT07048314
View directory record Official record
Conditions
Erectile Dysfunction, Prostate Cancer
Interventions
Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in the OR, Placebo in clinic
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Sep 30, 2026, 5:59 AM EDT